A cautionary tale for clinical trial collaborators
AstraZeneca ended a tie-up with Asher, and then set off on its own.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
Bispecific cytokine delivers for Innovent at last
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Ipsen sees a future in gammadelta T-cells
The company will acquire ImCheck for €350m.
ESMO 2025 movers – FDA volte-face to the rescue
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
